Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 15/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383686 | 0.90 | CETP (0.52) | CETP | |
| SCHEMBL12247790 | 0.90 | CETP (0.52) | CETP | |
| SCHEMBL12247792 | 0.90 | CETP (0.52) | CETP | |
| SCHEMBL2381379 | 0.89 | CETP (0.48) | CETP | |
| SCHEMBL2380949 | 0.88 | CETP (0.57) | CETP | |
| SCHEMBL2378484 | 0.85 | CETP (0.49) | CETP | |
| SCHEMBL13264532 | 0.84 | CETP (0.50) | CETP | |
| SCHEMBL2380123 | 0.84 | CETP (0.59) | CETP | |
| SCHEMBL4749483 | 0.84 | CETP (0.59) | CETP | |
| SCHEMBL12247780 | 0.84 | CETP (0.59) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012963-B2 | 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012963-B2 | 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012963-B2 | 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | KUO GEE-HONG | 2010-09-09 | — | — | US | disclosed |
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | KUO GEE-HONG | 2010-09-09 | — | — | US | disclosed |
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | KUO GEE-HONG | 2010-09-09 | — | — | US | disclosed |
| US-7749995-B2 | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7749995-B2 | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| EP-2023934-A2 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007134149-A2 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134149-A2 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | CETP 1/4885TNKS2 248/4885BRD4 68/4885 |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | CETP 1/4885TNKS2 248/4885BRD4 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.